It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
The most precise assessment of ion channel and transporter function, enabling confident decisions to drive drug discovery.
At Sygnature Discovery, we design studies to meet your needs, from early target validation to hit identification and downstream lead optimization. Our electrophysiology studies are tailored to:
Guide selectivity and liability knowledge to enable better decisions
Validate challenging targets and characterize channel variants
Identify novel ion channel modulators via high-throughput screening
Advance structure-activity relationship understanding through robust, scalable assays
Interrogate mechanism of action, including gating behavior, kinetics, use/state dependence and reversibility
Platform Overview
We offer a suite of electrophysiology platforms that can be deployed individually or combined as part of multi-platform screening cascades, based on target biology, throughput needs, and study objectives.
Automated Patch Clamp
High-throughput electrophysiological recordings with precise assay control for hit identification and lead optimization.
Two-Electrode Voltage Clamp
Gold-standard resolution for kinetic characterization and mechanistic studies.
Solid-Supported Membrane-Based Electrophysiology
Sensitive analysis of electrogenic transporters and organellar ion channels using state-of-the-art electrophysiology platforms.
Custom Study Design
Our electrophysiology studies are fully customized to your target and designed to meet your objectives.
Plate plans and control Flexible plate plans to maximize data output including placement and frequency of controls, randomization, replicate structures.
Screening Cascades Configured for efficient, time-sensitive triaging, from hit confirmation to potency and selectivity / safety studies.
Protocols aligned to target biology Customized protocols, stimulation paradigms, compound applications, and analysis tailored to your target.
Reporting formats From raw and processed files in your format of choice to concise data packs, our flexible approach provides meaningful data, fast.
Why Choose Sygnature Discovery for Electrophysiology Support?
We combine deep electrophysiology expertise with a flexible suite of platforms that supports both mechanistic studies and scalable, time-sensitive screening cascades.
Our team delivers high-quality, reproducible datasets across multiple electrophysiology platforms including automated / manual patch clamp, two-electrode voltage clamp and solid-supported membrane electrophysiology.
With complete flexibility in plate design, assay configuration and reporting, we deliver world-class electrophysiology through a single connected team, ensuring outputs that inform meaningful discovery to candidate selection.
Delivering Custom Cell-Based Tools for Ion Channel Drug Discovery
Ebook
Drug Discovery research heavily relies on cell-based assay systems to investigate cellular functions and processes, and to help understand the effect of modulating specific molecular targets. Challenges associated with the use of primary cultures, such as availability, scalability, and cost, make recombinant cellular systems indispensable for drug discovery. High quality recombinant cell lines provide robust, reliable data and support large-scale high throughput screening, as well as enabling downstream medicinal chemistry-driven…
GABAA receptor screening enables detailed evaluation of subtype-selective modulation using automated electrophysiology. Sygnature Discovery supports CNS…
Case Studies
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Advanced transporter assays and electrophysiology deliver robust, high-throughput data for hit identification, validation, and lead optimization in drug discovery.
